Drugs /

rly-4008

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, FGFR2 inhibitor RLY-4008 binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.

Clinical Trials

View Clinical Trials for rly-4008

Rly-4008 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating rly-4008, 1 is phase 1 (1 open).

FGFR2 Amplification, FGFR2 Fusion, and FGFR2 Mutation are the most frequent biomarker inclusion criteria for rly-4008 clinical trials.

Intrahepatic cholangiocarcinoma and malignant solid tumor are the most common diseases being investigated in rly-4008 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rly-4008
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rly-4008 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
fgfr2 inhibitor rly-4008, rly4008, rly 4008
Drug Target(s) [2]:
FGFR2
NCIT ID [1]:
C174208

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.